materials-summit-separation-summit-2018-posters

Page 38

O c t o b e r 1 9 - 2 0 , 2 0 1 8 | T o k y o , J a p a n

Materials Summit 2018 & Separation Summit 2018

Materials Science and Nanotechnology

Volume 2

ADVANCED MATERIALS AND POLYMER SCIENCE

SEPARATION TECHNIQUES

International Conference on

International Conference and Expo on

Joint Event on

OF EXCELLENCE

IN INTERNATIONAL

MEETINGS

YEARS

Mater Sci Nanotechnol 2018, Volume 2

TRANSITION METAL COMPLEXES/ORGANOMETALLIC COMPOUNDS AS

ANTICANCER/ANTI-HIV DRUGS OR IN PHARMACEUTICAL INDUSTRY

Prakash MMS Kinthada

Sree Vidyanikethan Engineering College, India

ancer is a dreadful disease and any practical solution in combating this disease is of paramount importance to public health.

Cancer patients have burdened by drug induced toxic side effects, and no turned to seek help from the complementary and

alternative medicine hoping for a better cure. Research on platinum-based drugs and non-platinum-based drugs is a Multi-Million

Dollar Industry in USA and there is every need to produce safe drugs for the cure of this monstrous disease. Flavonoids have a long

history of use in traditional medicines in many cultures. This talk would mainly encompass different transition metal complexes/

organometallic compounds that are presently used as drugs, especially anticancer and anti-HIV drugs, apart fromanti-inflammatory,

antimicrobial, antibacterial and diseases like arthritis and Parkinson’s disease etc. This talk would mainly focus on the use of

medicinal chemistry and its application to drug design and development in pharmaceutical industry, especially transition metal

complexes and organometallic compounds viz. gold, platinum, palladium and ruthenium apart from copper, cobalt, iron, nickel,

zinc, cadmium etc. The main emphasis of this talk would be on different class of ligands, their Schiff’s bases and transition metal

complexes especially Au, Pt, Pd and Ru, with the main aim of designing, developing very novel small molecules, as possible and

extremely potential candidates as anti-cancer and anti-HIV drugs. The talk would provide an overview of current programs being

undertaken in our laboratories, especially focused on the development of potent ligands capable of recognizing binding sites and

diverse strategies employed by my group for elucidation of anti-cancer and anti-HIV drug leads to circumvent the problem caused

by cis-platin.